AbbVie Appoints CEO Robert A. Michael as Chairman of the Board of Directors
Richard A. Gonzalez to retire from the board of directors effective July 1, 2025
Richard A. Gonzalez to retire from the board of directors effective July 1, 2025
The new facility will enhance AbbVie’s chemical synthesis capacity to support domestic production of current and next-generation neuroscience, immunology, and oncology medicines
Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia
Subscribe To Our Newsletter & Stay Updated